ArticleFrontiers in oncology2021
Siglec-15 Promotes Tumor Progression in Osteosarcoma
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis.Frontiers in oncology · 2022Pooled it
- AhR-Siglec-15 axis regulates lysosomal Ca2+ release for sonic hedgehog medulloblastoma growth via TRPML1.Protein & cell · 2026Article
- miR-486-3p Suppresses Osteosarcoma Proliferation and Migration by Targeting the SPRED1-MAPK/ERK Pathway.Biochemical genetics · 2026Article
- Gypenoside LI Inhibits Renal Cancer Proliferation by Affecting Lipid Metabolism through the Upregulation of Dual-Specificity Phosphatase 1.Combinatorial chemistry & high throughput screening · 2026Article
- Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression.Journal of experimental & clinical cancer research : CR · 2025Article
- Epithelial-Mesenchymal Transition in Osteosarcoma as a Key Driver of Pulmonary Metastasis.Cancers · 2025Review
- Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy.Korean journal of clinical oncology · 2025Review
- Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA.Molecular oncology · 2025Article
- A prognostic model for stomach adenocarcinoma based on hypoxia- and immune-related genes.Archives of medical science : AMS · 2025Article
- MAP3K19 Promotes the Progression of Tuberculosis-Induced Pulmonary Fibrosis Through Activation of the TGF-β/Smad2 Signaling Pathway.Molecular biotechnology · 2024Article
- Importance of CD8 Tex cell-associated gene signatures in the prognosis and immunology of osteosarcoma.Scientific reports · 2024Article
- Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.Scientific reports · 2024Article
- What role does GPR65 play in the progression of osteosarcoma? Its mechanism and clinical significance.Cancer cell international · 2024Article
- Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma.Scientific reports · 2024Article
- Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.Frontiers in oncology · 2024Article
- Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia.Cancer research communications · 2023Article
- PSKH1 affects proliferation and invasion of osteosarcoma cells via the p38/MAPK signaling pathway.Oncology letters · 2023Article
- Article
- Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence and metastasis are important features of osteosarcoma (OS) that cause its poor prognosis. Aberrant expression of Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been reported in various kinds of cancers. However, the expression and function of Siglec-15 in OS remain unclear. In cultured OS cells (143B cells and MNNG/HOS cells) and their xenograft mouse models, we found that downregulation of Siglec-15 could inhibit the proliferation, migration and invasion of by inducing epithelial-mesenchymal transition (EMT)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.